Citalopram in the treatment of depression and other potential uses in psychiatry

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 675-689

  Tan, Jennifer Y ^a   Levin, Gary M ^b  

^a Capital District Psychiatric Center   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PERICIAZINE; PERPHENAZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZUCLOPENTHIXOL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; NEUROTRANSMISSION; PSYCHOPHARMACOLOGY; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SOMNOLENCE; TREATMENT PLANNING; UNITED STATES; XEROSTOMIA;

CITALOPRAM; DEPRESSION; DRUG INTERACTIONS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 0033003124     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.675.31538     Document Type: Review

References (76)

1. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(suppl 1):19-26.
2. Bjerkenstedt L, Hyckt L, Overø KF, Lingjærde O. Relationship between clinical effects, serum drug concentration, and serotonin uptake inhibition in depressed patients treated with citalopram. Eur J Clin Pharmacol 1985;28:553-7.
3. Ascher JA, Cole JO, Colin JN. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
4. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-15.
5. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg BB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
6. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
7. Christensen AV, Fjalland B, Petersen V, et al. Pharmacology of a new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties. Eur J Pharmacol 1977;41:153-62.
8. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm 1992;88:157-60.
9. Stahl SM, ed. Antidepressants and mood stabilizers. In: Essential psychopharmacology. New York: Cambridge University Press, 1995:131-66.
10. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors. Behav Brain Res 1996;73:281-3.
11. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
12. Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jorgensen T, Sidhu J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998;54:237-42.
13. Kragh-Sørensen P, Overø KF, Petersen OL, Jensen K, Parnas W. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol 1981;48:53-60.
14. Priskorn M, Larsen F, Segonzac A, Moulin M. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol 1997;52:241-2.
15. Overø KF. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:311-18.
16. Bouchard JM, Delauney J, Delisle JP, et al. Citalopram versus maprotiline: a controlled, clinical multicenter trial in depressed patients. Acta Psychiatr Scand 1987;76:583-92.
17. Timmerman L, DeBeurs P, Tan BK, et al. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. Int Clin Psychopharmacol 1987;2:239-53.
18. De Wilde J, Mertens C, Overø F, Petersen H. Citalopram versus mianserin - a controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 1985;72:89-96.
19. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-8.
20. Rochat B, Amey M, Gillet M, Meyer U, Baumann P. Identification of three cytochrome P-450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10.
21. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P-450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280:927-33.
22. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-17.
23. Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996;18: 111-17.
24. Overø KF, Toft B, Christophersen L, Gylding-Sabroe JP. Kinetics of citalopram in elderly patients. Psychopharmacology 1985;86:253-7.
25. Forest Pharmaceuticals. Celexa (citalopram) package insert. St. Louis, MO;1998.
26. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P-4502D6 activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
27. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen E, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine, and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
28. Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. Clin Pharmacokinet 1997;33:454-71.
29. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-1.
30. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993;71:1002-9.
31. Baettig D, Bondolfi G, Montalsi S, Amey M, Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur J Clin Pharmacol 1993;44:403-5.
32. Gram LF, Hansen MGJ, Sindrup SH, et al. Citalopram: interaction studies with levopromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24.
33. Syvalahti EKG, Taiminen T, Saarijärvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997;25:24-32.
34. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44:199-202.
35. Duncan D, Sayal K, McConnell H, Taylor D. Antidepressant interactions with warfarin. Int J Psychopharmacol 1998;13: 87-94.
36. Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997;20:419-33.
37. Montgomery SA, Rasmussen JGC, Lyby K, Connor P, Tanghøj P. Dose-response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992;6(suppl 5):65-70.
38. Feighner J, Overø K, Fieve R, Carman J, Cunningham L, Schwartz G. Fixed dose comparison of citalopram versus placebo in the treatment of outpatients with moderate to severe depression. Presented at the annual meeting of the American Psychiatric Association, San Diego, CA, May 21, 1997.
39. Mendels J, Overø K, Kiev A, Fabre L, Schwartz G. Citalopram versus placebo in the treatment of outpatients with moderate to severe depression. Presented at the annual meeting of the American Psychiatric Association, San Diego, CA, May 21, 1997.
40. Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987;75:478-86.
41. Shaw DM, Thomas DR, Briscoe MH, et al. A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 1986;149:515-17.
42. Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgȧrd S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicenter clinical study. Int Clin Psychopharmacol 1994;9(suppl 1):41-8.
43. Bowden C, Mackle M. Citalopram vs imipramine in the treatment of inpatient depression: results from a double-blind placebo-controlled study. Presented at the annual meeting of the American Psychiatric Association, Toronto, Ontario, Canada, May 20-June 4, 1998.
44. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-31.
45. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
46. Bougerol T, Scotto J, Patris M, Strub N, Lemming O, Petersen H. Citalopram and fluoxetine in major depression - comparison of two clinical trials in psychiatrist setting and in general practice. Clin Drug Invest 1997;14:77-69.
47. Haffmans PMJ, Timmerman L, Hoogduin CAL, et al. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 1996;11:157-64.
48. Montgomery SA, Pedersen V, Tanghøj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994;9(suppl 1):35-40.
49. Flicker C, Tanghøj P, Tsay J. Meta-analysis of placebo-controlled trials of citalopram in the treatment of depression. Presented at the annual meeting of the American Psychiatric Association, Toronto, Ontario, Canada, May 20-June 4, 1998.
50. Montgomery SA, Rasmussen JGC, Tanghøj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-8.
51. Dencker SJ, Petersen HEH. Side-effect profile of citalopram and reference antidepressants in depression. Presented at the XXII Nordiske Psyckiater-Kongres, Reykjavik, Iceland, August 10-13, 1988.
52. Muldoon C. The safety and tolerability of citalopram. Int Clin Psychopharmacol 1996;11(suppl 1):35-40.
53. Overø KF, Rasmussen SL, Tanghøj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. Presented at the annual meeting of the American Psychiatric Association, Toronto, Ontario, Canada, May 20-June 4, 1998.
54. Lepola DM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-34.
55. Michael A, Herrod JJ. Citalopram-induced decreased libido. Br J Psychiatry 1997;171:90.
56. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Br J Psychiatry 1990;157:894-901.
57. Lazowick AL, Levin GM. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995;29:1284-5.
58. Ostrom M, Eriksson A, Thorson J, et al. Fatal overdose with citalopram. Lancet 1996;348:339-40.
59. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59(suppl 15):42-8.
60. Personne M, Sjöberg G, Persson H. Citalopram overdose - review of cases treated in Swedish hospitals. Clin Toxicol 1997;35:237-40.
61. Grundemar L, Wohlfart B, Lagerstadt C, Bengtssen F, Eklundh G. Symptoms and signs of severe citalopram overdose. Lancet 1997;349:1602.
62. Ragneskog H, Eriksson S, Karlsson I, Gottfries CG. Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram. Int Psychogeriatr 1996;8: 659-68.
63. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenier clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-45.
64. Pollock B, Mulsant BH, Sweet R, et al. An open pilot study of citalopram for behavioral disturbances of dementia. Am J Geriatr Psychiatry 1997;5:70-8.
65. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-1104.
66. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993;342:837-9.
67. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992;6(suppl 5):21-39.
68. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioral, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 1997;22;332-40.
69. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-53.
70. Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997;96:343-6.
71. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997;17:267-71.
72. Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 1997;7:157-66.
73. Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998;49:79-82.
74. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the national comorbidity study. J Affect Disord 1997:45:19-30.
75. Greenberg PE, Stiglin LE, Findelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54: 405-18.
76. Stewart A. Choosing an antidepressant: effectiveness-based pharmacoeconomics. J Affect Disord 1998;48:125-33.